Jinhe Biotechnology CO., LTD.
Jinhe Biotechnology CO., LTD. produces and sells veterinary medicines in China. The company offers chlortetracycline feed grade, an antimicrobial drug for the inhibition and treatment of white dysentery, enteritis, pneumonia, typhoid, paratyphoid, choler…
Drug Manufacturers - Specialty & Generic
CN, Dalian [HQ]
Cash Flow Statements
- Primary View
- Secondary View
Currency
USD
Value Format
100 K
M
B
T
Scope
Options
Old New
Mark < 0
Mark > 0
Tools
Switch To Charts
002688.SZ SRC | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash Flow from Operating Activities | 198 | 124 | 152 | 258 | 282 | 117 | 27 | 292 | 214 | (58) | 148 | 88 | 106 | 118 | 23 |
Depreciation and Amortization | 179 | 155 | 132 | 119 | 99 | 86 | 72 | 56 | 54 | 41 | 37 | 38 | 38 | 34 | 31 |
Deferred Taxes | 6 | 2 | 2 | (9) | (9) | 2 | (29) | 103 | (0.53) | - | - | - | - | - | - |
Stock Based Compensation | 7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Change in Working Capital | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Change in Accounts Payable | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Flow from Investing Activities | (534) | (386) | (397) | (204) | (184) | (192) | (284) | (456) | (371) | (347) | (160) | (51) | (39) | (54) | (23) |
Capital Expenditures | (457) | (402) | (383) | (204) | (178) | (170) | (196) | (128) | (142) | (348) | (160) | (34) | (39) | (54) | (23) |
Acquisitions (Net) | (60) | 17 | (19) | 0.00 | (6) | (20) | (3) | (86) | (4) | 348 | 160 | - | - | 54 | - |
Investments (Purchases) | (9) | (4) | (0.10) | (0.10) | - | (1) | (28) | (225) | (276) | (130) | (30) | (17) | (0.07) | (1) | - |
Sales/Maturities of Investments | 3 | 0 | 5 | (0.00) | - | - | 26 | 40 | 51 | 131 | 30 | - | - | 1 | - |
Other Investing Activities | (10) | 2 | (0.30) | (0.30) | 1 | (20) | (83) | (55) | 0.05 | (348) | (160) | (34) | - | (54) | (23) |
Cash Flow from Financing Activities | 413 | 150 | 448 | 27 | (185) | 153 | 253 | 207 | 196 | 278 | (86) | 248 | (40) | (79) | 5 |
Issuance of Debt | 86 | (90) | 201 | 74 | (86) | 80 | (3) | 44 | 41 | (126) | (98) | 285 | 26 | (16) | 5 |
Repayment of Debt | (600) | (995) | (1,573) | (1,102) | (900) | (677) | (432) | (827) | (302) | (170) | (220) | (355) | (307) | (383) | (334) |
Dividends Paid | (75) | (40) | (63) | (158) | (158) | (65) | (141) | (98) | (40) | (31) | (56) | (14) | (16) | (15) | (22) |
Stock-Based Compensation (Financing Activity) | |||||||||||||||
Other Financing Activities | (38) | 1,186 | 2,126 | 1,353 | 937 | 896 | 828 | 1,133 | 538 | 480 | 190 | 618 | 283 | 320 | 362 |
Net Change in Cash | 86 | (90) | 201 | 74 | (86) | 80 | (3) | 44 | 41 | (126) | (98) | 285 | 26 | (16) | 5 |
Cash at Beginning of Period | 410 | 501 | 299 | 225 | 311 | 231 | 235 | 190 | 148 | 275 | 373 | 87 | 61 | 77 | 71 |
Effect of Forex Changes on Cash | 9 | 21 | (2) | (7) | 1 | 1 | 0.03 | 1 | 1 | 0.06 | (0.02) | (0.02) | (0.05) | (0.02) | 0.00 |
Cash at End of Period | 497 | 410 | 501 | 299 | 225 | 311 | 231 | 235 | 190 | 148 | 275 | 373 | 87 | 61 | 77 |